Workflow
港股异动 | MIRXES-B(02629)涨近9%创新高 公司在基于miRNA的癌症早期检测领域优势显著
MIRXESMIRXES(HK:02629) 智通财经网·2025-08-15 03:08

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and other disease screening [1] - The flagship product, GASTROClear™/觅小卫™, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the US FDA [1] - GASTROClear™ has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - According to Guoyuan International, the company holds significant technological, product, and market advantages in the field of miRNA-based early cancer detection, positioning it as a global leader [1] - Everbright Securities International noted the vast market potential for global cancer screening, highlighting high industry entry barriers [1] - GASTROClear™ is the only approved molecular diagnostic IVD product for gastric cancer screening globally, holding the largest market share of 66.3% in the Southeast Asian miRNA liquid biopsy gastric cancer screening market as of 2023 [1]